Date
Monday, December 8, 2025

 

Time
1:00 PM (UTC-04:00) Eastern Time (US & Canada)

 

Duration
60 minutes

 

Description

In the final chapter of our Pulmonary Fibrosis webinar series, Dr Saad Ashraf will discuss FDA-approved nerandomilast and what its introduction means for clinicians, payers, and patients living with idiopathic and progressive pulmonary fibrosis. 

Gain insight into the data behind nerandomilast’s approval, how it may fit into current treatment strategies, and what this milestone means for the future of management. 

 

This is a non-CME event. By registering for this program, you consent to share your registration information with the program's sponsor.